Navigation Links
Optimizing Quality Control Data Management

Analytical Goals, Total Error based upon Biological Variation setup dialog box in Unity Real Time

Unity Interlaboratory Program

Interlaboratory quality control programs are a broader strategy than just running controls and comparing them to the intralaboratory expected results. With an interlaboratory comparison program, laboratories submit their data to a central database and receive back reports comparing their results statistically to other laboratories in defined consensus groups running the same or similar tests. In this manner, a laboratory can compare its performance to available consensus groups to determine if its performance is as good as those using the same method. If not, the laboratory knows that it should investigate possible corrections to improve results. With Unity Real Time, Bio-Rads Unity Interlaboratory Program gives the laboratory additional documented confidence that their results are satisfactory, and provides laboratories additional confidence that they will pass blind proficiency surveys offered by external quality assessment programs.

References

  1. Fraser Callum, Biological Variation: From Principles to Practice, AACC Press, Washington DC, 2001 (available at www.aacc.org)
  2. Ricos Carmen et al., Current databases on biological variation: pros, cons and progress, Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 59, No. 7, November 1999, 491-500 (an update is available at www.westgard.com)
  3. 42 CFR (Code of Federal Regulations), Ch. IV (10-1-01 Edition), Part 493
  4. Westgard James O, Basic Planning for Quality, Westgard QC, Inc., 2000
  5. Westgard James O, Basic QC Practices, Westgard QC, Inc., 1998
  6. Petersen Per-Hyltoft et al., Combination of analytical quality specifications based on biological within- and between-subject variation, Annals of Clinical Biochemistry 2002;39:543-550

'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Quality Control Systems for Every Laboratory Application
2. Choosing Lab Quality Management Software
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. Tight Glycemic Control in the ICU
5. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Optimizing Quality Control Data Management
(Date:11/24/2009)...ov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiaryo...sCorporateResearch(NYSE: SI ),todayannouncedthatit...2009episodeofCBS, TheEarlyShow duringasegmentinwhi...eviewedfivewinningproductsfromthepublication,s2009...dely-viewedtelevisionmorningnewstalkshowbroadcastb...
(Date:11/24/2009)...PRNewswire/--AmbitBiosciencesCorporationannouncedt...AC220,anovelsecondgenerationFLT3inhibitor,inAMLatt...)tobeheldinNewOrleans,LA,December5-8,2009.Anoralpr...lPhaseImonotherapysafetystudyinadultswithacutemyel...bepresentedevaluatingtheeffectofAC220monotherapyan...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--EchoTherapeutics,Inc....e-freeSymphony(TM)tCGMSystemasanon-invasive,wirele...temanditsPrelude(TM)SkinPrepSystemfortransdermaldr...ChairmanandChiefExecutiveOfficer,willpresentatthe1...nce,sponsoredbytheNewYorkSocietyofSecuritiesAnalys...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Echo Therapeutics to Present at the New York Society of Security Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 1Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 2Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV 14655 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 1YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 14651 4Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35
...oBio Corporation is,presenting safety and efficacy...alis (cold sores) and onychomycosis (toe nail fung...of Dermatology (AAD), being held February,1-5, 200...cate that the company,s topical lotions,composed o...and antifungal,effects without safety concerns or ...
...ts targeted as part of innovative,Therapeutics Dev...f its ongoing,efforts to do whatever it takes to s...ure for Parkinson,s disease, The Michael J. Fox,Fo...o $3 million in total,funding to four industry tea...ser to the clinic. The awards were granted under M...
Other Medicine Technology:NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 2NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:11/24/2009)...ting firm LocumTenens.com, a leading provider of t...e its agreement with VHA Inc., a national healthca... assignments. , Alpharett...uiting firm LocumTenens.com , a leading provider...nounce its agreement with VHA Inc., a national hea...
(Date:11/24/2009)...use of inflammatory bowel disease is largely unkno... 2009 Advances in Inflammatory Bowel Diseases, the...inical & Research Conference, December 3-6 in ...mutation for Crohn’s disease. , ...9 -- The molecular cause of inflammatory bowel dis...
(Date:11/24/2009)...SNewswire/--GovernorEdwardG.Rendelltodayannouncedt...ccinatedduringtheweekendatpublichealthclinicsheldb..., "Withthefederalgovernmentunabletoprovideaccur...ofH1N1vaccine,distributionhasbeenchallenging,"said...ccinedistributionprocessinPennsylvania.Holdingpubl...
(Date:11/24/2009)...e/--AgitoNetworks,Inc.,thecompanydeliveringinnovat...titwashonoredintheEverythingChannelTechInnovatorAw....0.EverythingChannel,sTechInnovatorAwardscelebrate...tdriveadvancesthroughoutthetechnologychannel. ,...pplicationsforthe2009EverythingChannelTechInnovato...
(Date:11/24/2009)...wire/--Nextmonth,UnitedHealthcarewilloffertwofreeM...ricanseniorsunderstandthebasicsofMedicare.Followin...174;Goldclass,aLatin-infusedfitnessprogramthatblen.... ,, UnitedHealthcarewilloffertheseseminarsinSp...arningabouttheirhealthcareoptions. Thereareapprox...
Breaking Medicine News(10 mins):Health News:VHA Names LocumTenens.com as Preferred Physician Staffing Vendor 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 2Health News:Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 3Health News:UnitedHealthcare To Offer Seniors Hispanic-Centered Medicare Education Seminars Combined With a Latin-Themed Fitness Program 2
...iscovery including solutions to tackle obesity, t...r and issues surrounding drugs used in sport and t...n Brighton next week. , The British Pharmacologic...ss the world. , Running from 16 to 18 December, t...
...Board of Medical Specialties (ABMS), the organizat...ialists in the United States, has appointed Richar...professional and scientific affairs. Hawkins will ...promote the science of ABMS Maintenance of Certifi...
...harmaceutical Companies, Inc. (NYSE: PRX ) today..., executive vice president and chief financial off...fessional opportunities. , , Lawrence A. Ke... Mr. Kenyon joins from Alfacell Corporation where ...
...ber 8, 2008, TooBusyWorking was launched as a next...s local nursing job openings from all major employ...has more local nursing job listings than CareerBui...s with information detailing commuting distance, s...
... malaria elimination can be achieved. A supplement...of articles reviewing the many aspects of the rese... of the supplement,s reviews charts the progress t...ferent vaccine strategy, since success will depend...
...rporation and Terumo,s,subsidiary, Terumo Cardiova...hey have entered into an agreement to settle all o...LLC. The companies have a number of lawsuits pend...All pending,disputes between the companies will be...
Other Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News: ABMS Appoints Richard Hawkins, MD, FACP as New Senior Vice President for Professional and Scientific Affairs 2Health News: ABMS Appoints Richard Hawkins, MD, FACP as New Senior Vice President for Professional and Scientific Affairs 3Health News:Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer 2Health News:Malaria Journal supplement evaluates steps toward elimination 2
...eoGen surgically implanted bone growth stimulator ... when surgery is already planned or when patient c...s totally surgically implanted, patients are assur...on site 24 hours a day for up to 6 months. , ,...
BIG ADVANTAGE Cannulated Titanium Interference Screws
...rew ACL Interference Screw is indicated for graft ...and PCL reconstructions with bone-patellar tendon-... SmartScrew ACL provides easy and atraumatic inser... type. The unique Self-Reinforced 96L/4D copolymer...
ADVANTAGE Titanium Cannulated Interference Screws
Medicine Products: